Trials Sponsors Conditions Drugs Pricing

Conditions

SARS-CoV-2 Infection SARS-CoV-2 Vaccination

Outcome Measures

Primary Outcomes (1)

The result of Corona-T-test
positive, negative, or inconclusive (gray-zone)
1 week

Study Arms (3)

Vaccinated

SARS-CoV-2 vaccination with 'Sputnik V' (Gam-COVID-Vac) in a period 7-14 days after the second vaccination before recruitment

Diagnostic Test: Corona-T-test

Convalescents

PCR (polymerase chain reaction) confirmed COVID-19 in a period 14-45 days before recruitment

Diagnostic Test: Corona-T-test

Healthy donors

No self-reported COVID-19 infection

Diagnostic Test: Corona-T-test

Interventions

Corona-T-testDiagnostic test

Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells

ConvalescentsHealthy donorsVaccinated

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The attendees of the LTT 'DNKOM' were screened for the inclusion/exclusion criteria with a questionnaire and the above-mentioned serology tests.

You may qualify if:

Participants aged 18 and above

Sponsors & Collaborators

DNKOM LLC
Othercollaborator
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Othercollaborator

Study Sites (1)

National Research Center for Hematology

Moscow, 125167, Russia

Biospecimen

Retention: SAMPLES WITH DNA

frozen blood

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

Grigory A Efimov, MD PhD
National Research Center for Hematology
PRINCIPAL INVESTIGATOR

Enrollment

220 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 8, 2021

First Posted

December 21, 2021

Study Start

July 7, 2021

Actual (reported)

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Vaccinated

Convalescents

Healthy donors

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Vaccinated

Convalescents

Healthy donors

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations